Work

Anifrolumab for the treatment of refractory chilblain lupus erythematosus

Year: 2023

Type: article

Abstract: Chilblain lupus erythematosus (CHLE) is a subtype of chronic cutaneous lupus erythematosus (CLE) that manifests often as pruritic and painful erythematous-violaceous papules and plaques at acral regions. The pathogenesis of CHLE is not entirely known; however, the familial TREX1 mutation is implicated, and studies suggest that type I interferon (IFN)-driven signaling contributes to the disease. Additionally, optimal management of recalcitrant disease is unclear.1 Here, we describe the workup and successful treatment of 2 patients with recalcitrant CHLE using anifrolumab, a type I IFN receptor antagonist.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2023.10.020

Authors: Michael J. Woodbury, Katherine Nabel Smith, Jeffrey S. Smith, Joseph F. Merola

Institutions: Brigham and Women's Hospital, Harvard University, The University of Texas Southwestern Medical Center

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $675